PURPOSE: Social cognition captures affect recognition, social cue perception, "theory of mind," empathy, and attributional style. The aim of our study was to assess social cognition in @entity161 inpatients being treated with first-generation antipsychotic drugs (FGAs), n=28 ( @entity21886 and @entity1767 , FGAs) or with second-generation antipsychotic drugs (SGAs), n=56 ( @entity1037 and @entity1088 , SGAs). SUBJECTS AND METHODS: Eighty-four @entity1 completed the Facial Expression Recognition Test, the Voice Emotion Recognition Test, the Short Recognition Memory Test for Faces, and the Reading the Mind in the Eyes Test. @entity1 also completed the Visual Object and Space Perception Test (VOSP) as a control task, which would not engage social cognition. The @entity1 were compared with fifty healthy controls matched for age and gender. RESULTS: There were no significant differences on social cognitive performance between the @entity22802 - and SGA-treatment groups. Nor was @entity1037 superior to @entity1088 , FGAs or both. However, @entity1 treated with FGAs performed significantly worse on VOSP compared to both groups treated with SGAs, a 10% difference. CONCLUSIONS: We cannot conclude that SGAs were associated with better social cognition than FGAs. However, there were small but significant advantages for SGAs in non-social visual processing function, as evaluated with the VOSP.

Social cognition and visual perception in XXXX inpatients treated with first-and second-generation antipsychotic drugs.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1088 :: ('MESH:D003024', 'Chemical') :: ['clozapine'] @entity21886 :: ('MESH:D010546', 'Chemical') :: ['perphenazine'] @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia'] @entity1767 :: ('MESH:D006220', 'Chemical') :: ['haloperidol'] @entity1037 :: ('MESH:C076029', 'Chemical') :: ['olanzapine'] @entity22802 :: ('2243', 'Gene') :: ['FGA']
@entity161 :: (MESH:D012559,Disease) :: ['schizophrenia']
